7/1/2014 11:17:42 AM
BOSTON--(BUSINESS WIRE)--Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into an exclusive licensing and development agreement with Japanese global pharmaceutical company Eisai Co., Ltd., for Eisai's oncology drug, E6201.
Help employers find you! Check out all the jobs and post your resume.
comments powered by